{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:35:50Z","timestamp":1780918550429,"version":"3.54.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40121-023-00864-4","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T07:02:49Z","timestamp":1695798169000},"page":"2367-2386","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older"],"prefix":"10.1007","volume":"12","author":[{"given":"David","family":"Neveu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamala","family":"Mallett Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betzana","family":"Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"K\u00fcrzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydie","family":"Marcelon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep","family":"Singh Dhingra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"864_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3389\/fped.2018.00321","volume":"6","author":"S Nadel","year":"2018","unstructured":"Nadel S, Ninis N. Invasive meningococcal disease in the vaccine era. Front Pediatr. 2018;6:321.","journal-title":"Front Pediatr"},{"key":"864_CR2","unstructured":"Mbaeyi S, Duffy J, McNamara LA. Meningococcal disease. Centres for Disease Control and Prevention (CDC); 2021."},{"key":"864_CR3","unstructured":"Centers for Disease Control and Prevention. Surveillance. Antibiotic-resistant Neisseria meningitidis serogroup Y2019."},{"issue":"14","key":"864_CR4","doi-asserted-by":"publisher","first-page":"1800245","DOI":"10.2807\/1560-7917.ES.2019.24.14.1800245","volume":"24","author":"M Krone","year":"2019","unstructured":"Krone M, Gray S, Abad R, Skoczynska A, Stefanelli P, van der Ende A, et al. Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017. Euro Surveill. 2019;24(14):1800245.","journal-title":"Euro Surveill."},{"key":"864_CR5","unstructured":"Public Health England. Invasive meningococcal disease in England: annual laboratory confirmed reports for epidemiological year 2016\/2017. Health Protection Report (2017). 2018."},{"key":"864_CR6","unstructured":"Menveo\u00ae. Summary of product characteristics. 2020."},{"key":"864_CR7","unstructured":"European Centre for Disease Prevention and Control (ECDC). Factsheet about meningococcal disease. European Centre for Disease Prevention and Control (ECDC); 2019."},{"key":"864_CR8","unstructured":"Nimenrix\u00ae. Summary of product characteristics. 2021."},{"key":"864_CR9","unstructured":"(CDC) CfDCaP. Clinical update. 2017."},{"key":"864_CR10","unstructured":"U.S Food and Drug Administration. Menomune-A\/C\/Y\/W-135-prescribing information. 2019."},{"key":"864_CR11","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1017\/S0950268821000261","volume":"149","author":"D van der Vliet","year":"2021","unstructured":"van der Vliet D, Vesikari T, Sandner B, Martin\u00f3n-Torres F, Muzsay G, Forsten A, et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-na\u00efve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study. Epidemiol Infect. 2021;149:e50.","journal-title":"Epidemiol Infect"},{"key":"864_CR12","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1097\/INF.0000000000002832","volume":"39","author":"CI Baccarini","year":"2020","unstructured":"Baccarini CI, Simon MW, Brandon D, Christensen S, Jordanov E, Dhingra MS. Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine in healthy meningococcal-Na\u00efve children 2\u20139 years of age: a phase III, randomized study. Pediatr Infect Dis J. 2020;39:955\u201360.","journal-title":"Pediatr Infect Dis J"},{"key":"864_CR13","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1016\/j.vaccine.2020.03.017","volume":"38","author":"LJ Chang","year":"2020","unstructured":"Chang LJ, Hedrick J, Christensen S, Pan J, Jordanov E, Dhingra MS. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine. 2020;38:3560\u20139.","journal-title":"Vaccine"},{"key":"864_CR14","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1080\/21645515.2020.1733867","volume":"16","author":"G \u00c1\u00f1ez","year":"2020","unstructured":"\u00c1\u00f1ez G, Hedrick J, Simon MW, Christensen S, Jeanfreau R, Yau E, et al. Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study. Hum Vaccin Immunother. 2020;16:1292\u20138.","journal-title":"Hum Vaccin Immunother"},{"key":"864_CR15","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1016\/j.vaccine.2020.04.067","volume":"38","author":"A Esteves-Jaramillo","year":"2020","unstructured":"Esteves-Jaramillo A, Koehler T, Jeanfreau R, Neveu D, Jordanov E, Singh DM. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in \u226556-year-olds: a phase III randomized study. Vaccine. 2020;38:4405\u201311.","journal-title":"Vaccine"},{"key":"864_CR16","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1080\/21645515.2020.1733869","volume":"16","author":"T Vesikari","year":"2020","unstructured":"Vesikari T, Borrow R, Forsten A, Findlow H, Dhingra MS, Jordanov E. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a PHASE II randomized study. Hum Vaccin Immunother. 2020;16:1306\u201312.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"864_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2021.1902701","volume":"18","author":"FM Piazza","year":"2022","unstructured":"Piazza FM, Virta M, Paassilta M, Ukkonen B, Ahonen A, Esteves-Jaramillo A, et al. Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: a phase III, open-label, multi-center study. Hum Vaccin Immunother. 2022;18(1):1\u201310.","journal-title":"Hum Vaccin Immunother"},{"key":"864_CR18","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268821000698","volume":"149","author":"MS Dhingra","year":"2021","unstructured":"Dhingra MS, Namazova-Baranova L, Arredondo-Garcia JL, Kim KH, Limkittikul K, Jantarabenjakul W, et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study. Epidemiol Infect. 2021;149: e90.","journal-title":"Epidemiol Infect"},{"key":"864_CR19","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1080\/21645515.2020.1733868","volume":"16","author":"J Kirstein","year":"2020","unstructured":"Kirstein J, Pina M, Pan J, Jordanov E, Dhingra MS. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a phase II randomized study. Hum Vaccin Immunother. 2020;16:1299\u2013305.","journal-title":"Hum Vaccin Immunother"},{"key":"864_CR20","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1016\/j.vaccine.2020.06.013","volume":"38","author":"MS Dhingra","year":"2020","unstructured":"Dhingra MS, Peterson J, Hedrick J, Pan J, Neveu D, Jordanov E. Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: a phase III randomized study. Vaccine. 2020;38:5194\u2013201.","journal-title":"Vaccine"},{"key":"864_CR21","unstructured":"U.S Food and Drug Administration. Benefit-risk assessment for new drug and biological products. 2021."},{"key":"864_CR22","unstructured":"European Medicines Agency (EMA). Benefit-risk methodology project-work package 2 report: applicability of current tools and processes for regulatory benefit-risk assessment. 2010."},{"key":"864_CR23","unstructured":"U.S Food and Drug Administration. About CBER. 2018."},{"key":"864_CR24","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s40264-020-00984-7","volume":"43","author":"H Arlegui","year":"2020","unstructured":"Arlegui H, Bollaerts K, Salvo F, Bauchau V, Nachbaur G, B\u00e9gaud B, et al. Benefit-risk assessment of vaccines. Part I: a systematic review to identify and describe studies about quantitative benefit-risk models applied to vaccines. Drug Saf. 2020;43:1089\u2013104.","journal-title":"Drug Saf"},{"key":"864_CR25","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/pds.3636","volume":"23","author":"S Mt-Isa","year":"2014","unstructured":"Mt-Isa S, Hallgreen CE, Wang N, Callr\u00e9us T, Genov G, Hirsch I, et al. Balancing benefit and risk of medicines: a systematic review and classification of available methodologies. Pharmacoepidemiol Drug Saf. 2014;23:667\u201378.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"864_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/pds.3958","volume":"25","author":"D Hughes","year":"2016","unstructured":"Hughes D, Waddingham E, Mt-Isa S, Goginsky A, Chan E, Downey GF, et al. Recommendations for benefit-risk assessment methodologies and visual representations. Pharmacoepidemiol Drug Saf. 2016;25:251\u201362.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"864_CR27","first-page":"780","volume":"10","author":"N Andrews","year":"2003","unstructured":"Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10:780\u20136.","journal-title":"Clin Diagn Lab Immunol"},{"key":"864_CR28","unstructured":"(WHO) WHO. Meningococcal vaccines: WHO position paper. Releve epidemiologique hebdomadaire. 2011;86:521\u201339."},{"key":"864_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.vaccine.2011.10.068","volume":"30","author":"CJ Gill","year":"2011","unstructured":"Gill CJ, Ram S, Welsch JA, Detora L, Anemona A. Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source. Vaccine. 2011;30:29\u201334.","journal-title":"Vaccine"},{"key":"864_CR30","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1080\/21645515.2019.1593082","volume":"15","author":"J Findlow","year":"2019","unstructured":"Findlow J, Balmer P, Borrow R. A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines. Hum Vaccin Immunother. 2019;15:2491\u2013500.","journal-title":"Hum Vaccin Immunother"},{"key":"864_CR31","unstructured":"World Health Organization (WHO). The immunological basis for immunization series\u2014module 15: meningococcal disease (updated 2020). 2020."},{"key":"864_CR32","unstructured":"U.S Food and Drug Administration. Menactra\u00ae highlights of prescribing information. 2018."},{"key":"864_CR33","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1086\/527401","volume":"197","author":"MC Maiden","year":"2008","unstructured":"Maiden MC, Ibarz-Pav\u00f3n AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197:737\u201343.","journal-title":"J Infect Dis"},{"key":"864_CR34","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1586\/14760584.2015.1084232","volume":"14","author":"PA Kristiansen","year":"2015","unstructured":"Kristiansen PA, J\u00f8rgensen HJ, Caugant DA. Serogroup A meningococcal conjugate vaccines in Africa. Expert Rev Vaccin. 2015;14:1441\u201358.","journal-title":"Expert Rev Vaccin"},{"key":"864_CR35","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1080\/21645515.2018.1454570","volume":"14","author":"P Balmer","year":"2018","unstructured":"Balmer P, Burman C, Serra L, York LJ. Impact of meningococcal vaccination on carriage and disease transmission: a review of the literature. Hum Vaccin Immunother. 2018;14:1118\u201330.","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"864_CR36","first-page":"1035","volume":"94","author":"B Zambrano","year":"2023","unstructured":"Zambrano B, Peterson J, Deseda C, Julien K, Spiegel CA, Seyler C et al. Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study. Pediatr Res. 2023;94(3):1035\u201343.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"864_CR37","doi-asserted-by":"publisher","first-page":"2160600","DOI":"10.1080\/21645515.2022.2160600","volume":"19","author":"CA Robertson","year":"2023","unstructured":"Robertson CA, Jacqmein J, Selmani A, Galarza K, Oster P. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged 59 years: a phase III randomized study. Human Vaccines Immunother. 2023;19(1):2160600.","journal-title":"Hum Vaccin Immunother"},{"key":"864_CR38","unstructured":"MENQUADFI\u2122\u2014highlights of prescribing information. 2020."},{"key":"864_CR39","doi-asserted-by":"publisher","first-page":"2052657","DOI":"10.1080\/21645515.2022.2052657","volume":"18","author":"M Knuf","year":"2022","unstructured":"Knuf M, R\u00e4met M, Breinholt St\u00e6rke N, Bertrand-Gerentes I, Thollot Y, B\u2019Chir S, et al. Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-na\u00efve toddlers: a randomised, controlled trial. Hum Vaccin Immunother. 2022;18:2052657.","journal-title":"Hum Vaccin Immunother"},{"key":"864_CR40","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.2147\/IDR.S159952","volume":"12","author":"I Rivero-Calle","year":"2019","unstructured":"Rivero-Calle I, Raguindin PF, G\u00f3mez-Rial J, Rodriguez-Tenreiro C, Martin\u00f3n-Torres F. Meningococcal Group B vaccine for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B. Infect Drug Resist. 2019;12:3169\u201388.","journal-title":"Infect Drug Resist"},{"key":"864_CR41","unstructured":"U.S Food and Drug Administration. Structured approach to benefit-risk assessment in drug regulatory decision-making: draft PDUFA V implementation plan\u2014February 2013 (FISCAL YEARS 2013\u20132017). 2013."},{"key":"864_CR42","unstructured":"U.S Food and Drug Administration (Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research). Benefit-risk assessment for new drug and biological products. 2021."},{"key":"864_CR43","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1524-4733.2010.00725.x","volume":"13","author":"JJ Guo","year":"2010","unstructured":"Guo JJ, Pandey S, Doyle J, Bian B, Lis Y, Raisch DW. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group. Value Health. 2010;13:657\u201366.","journal-title":"Value Health"},{"key":"864_CR44","unstructured":"U.S Food and Drug Administration. Benefit-risk assessment in drug regulatory decision-making: draft PDUFA VI implementation plan (FY 2018\u20132022). 2018. Available at https:\/\/www.fda.gov\/files\/about%20fda\/published\/Benefit-Risk-Assessment-in-Drug-Regulatory-Decision-Making.pdf. Accessed October 03, 2022."},{"key":"864_CR45","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40271-017-0222-3","volume":"10","author":"EW de Bekker-Grob","year":"2017","unstructured":"de Bekker-Grob EW, Berlin C, Levitan B, Raza K, Christoforidi K, Cleemput I, et al. Giving patients\u2019 preferences a voice in medical treatment life cycle: the PREFER public-private project. Patient. 2017;10:263\u20136.","journal-title":"Patient"},{"key":"864_CR46","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","volume":"25","author":"JU R\u00fcggeberg","year":"2007","unstructured":"R\u00fcggeberg JU, Gold MS, Bayas J-M, Blum MD, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25:5675\u201384.","journal-title":"Vaccine"},{"key":"864_CR47","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","volume":"29","author":"JJ Sejvar","year":"2011","unstructured":"Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain\u2013Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29:599\u2013612.","journal-title":"Vaccine"},{"key":"864_CR48","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.vaccine.2016.05.023","volume":"35","author":"B Rath","year":"2017","unstructured":"Rath B, Gidudu JF, Anyoti H, Bollweg B, Caubel P, Chen Y-H, et al. Facial nerve palsy including Bell\u2019s palsy: case definitions and guidelines for collection, analysis, and presentation of immunisation safety data. Vaccine. 2017;35:1972\u201383.","journal-title":"Vaccine"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00864-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-023-00864-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00864-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T04:13:16Z","timestamp":1698207196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-023-00864-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["864"],"URL":"https:\/\/doi.org\/10.1007\/s40121-023-00864-4","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"assertion":[{"value":"23 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"David Neveu, Tamala Mallett Moore, Betzana Zambrano, Marie-Laure K\u00fcrzinger, Lydie Marcelon and Mandeep Singh Dhingra are Sanofi employees and may hold stocks\/shares. Aiying Chen was an employee of Sanofi at the time of the study was conducted, and held stocks during her employment at Sanofi; she is currently employed at Daiichi Sankyo, New Jersey, United States of America.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This analysis is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. All clinical studies evaluating MenACYW-TT were conducted in accordance with the Declaration of Helsinki as well as in accordance with the Quality Standards of the International Conference on Harmonization Good Clinical Practices.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}